Pfizer is winding down its Pfizer Ignite unit, a program that provided advisory and R&D services to early-stage biotech companies. Regulatory disclosures indicate the company is drawing down operations and ending the initiative that had been intended to foster relationships with startups and accelerate external innovation. The closure reflects a broader trend among large pharmas reassessing in-house incubator programs amid shifting strategic priorities and the need to focus capital on core pipelines. Pfizer cited internal strategy changes and commercial considerations in its disclosures. Early-stage biotechs that relied on Ignite for scientific input and access to Pfizer expertise will need to re-evaluate partnerships and service strategies; the move also reduces a conduit that previously linked small innovators to a major pharma’s resources.